CHOSA Oncology AB out-license clinical-stage cancer vaccine candidate to Magle Group
CHOSA Oncology AB, today announces that the company has out-licensed the clinical-stage therapeutic cancer vaccine candidate onilcamotide to Magle Group. Magle Group plans to further develop onilcamotide by use of its proprietary degradable starch microspheres (DSM) technology. The company sees a future potential to combine onilcamotide treatment with its already approved vascular embolic product EmboCept® S.Onilcamotide is a clinical-stage therapeutic cancer vaccine candidate targeting RhoC, an over-expressed protein in metastatic cancer cells. Onilcamotide is a peptide that forms a